Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESCALATOR: Deferasirox Extension in Beta-thalassemia
NCT00171301Phase 4Completed
- Sponsor
- Novartis
- Start
- Jun 2005
- Primary completion
- May 2008
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 4, open-label, single-arm trial of deferasirox in transfusion hemosiderosis and iron overload, sponsored by Novartis. Primary endpoints: Percentage of Participants With Treatment Success up to 3 Years and Absolute Change in Liver Iron Concentration up to 3 Years. Started Jun 2005; status: completed.
02
Drugs
deferasirox
03
Conditions
transfusion hemosiderosisiron overload
Beyond the preview
Go deeper on NCT00171301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00171301.